TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06052176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Infusion
Description: Intravenous human serum albumin to be given at 1.5g/kg ideal body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin Infusion
Description: Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
Study: NCT06630091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: 150 mg once per day by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (max: 2 mg) by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg by PO
Study: NCT06188962

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-informed school-based counselling
Description: Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
Study: NCT04967508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara® (Ustekinumab)
Description: Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17 (Proposed Ustekinumab Biosimilar)
Description: Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB17 (Proposed Ustekinumab Biosimilar)
Description: Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.
Study: NCT05104476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for infusion
Study: NCT05580172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RH324
Description: polymolecular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RH324
Description: polymolecular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RH324
Description: polymolecular
Study: NCT05685368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT for Race Related Stress
Description: This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
Study: NCT06088316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group A : Amoxicillin Esomeprazole HDDT
Description: Group A - Amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group-B : Levofloxacin triple therapy
Description: Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
Study: NCT05362006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exopulse Mollii Suit
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exopulse Mollii suit (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study: NCT06484868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Study: NCT05471375

Intervention type: OTHER
Intervention: Database Entry
Description: Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments

Intervention type: OTHER
Intervention: Database Entry
Description: Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
Study: NCT04676880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)
Description: Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
Study: NCT06055439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHM-2101 CAR-T cells
Description: Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
Study: NCT05824377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Feeds
Description: Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Bolus Feeds
Description: Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
Study: NCT05534100

Intervention type: DEVICE
Intervention: Biostrap EVO Wristband
Description: Participants in both groups will wear the Biostrap wearable device

Intervention type: DEVICE
Intervention: Biostrap EVO Wristband
Description: Participants in both groups will wear the Biostrap wearable device
Study: NCT05804604

Intervention type: PROCEDURE
Intervention: Surgical treatment of proximal femur fracture and blood sample test
Description: Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB

Intervention type: PROCEDURE
Intervention: Blood sample test
Description: Analysis of serum concentration of: SHBG, CTX - I, CK-MB
Study: NCT06386562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program
Description: The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support
Description: The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
Study: NCT05982353

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PTFE application
Description: Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin sponge
Description: gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
Study: NCT05538988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
Study: NCT04976634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD via oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
Study: NCT04963803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Description: Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
Study: NCT04845646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: 5mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: 5mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: 5mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: 300mg/capsule
Study: NCT06232655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
Study: NCT04963803

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language Specific Attention Treatment
Description: This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Language Specific Attention Treatment
Description: This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
Study: NCT05753306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo stool and blood sample collection
Study: NCT06232655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
Study: NCT05753306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given via HIPEC
Study: NCT06232655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
Study: NCT05423093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Session Virtual Group Psychoeducational Session about Postpartum Depression
Description: Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
Study: NCT06375369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T)
Description: The intervention involves developing a standardized clinical pathway for these children requiring tracheostomy. The pathway comprises of a hospital to home directive, incorporating digital health solutions to support family, caregivers, and healthcare professionals. These digital supports include but are not limited to a Connect Care pathway, resources to aid families to make informed choices during the clinical decision-making process, education modules and high-fidelity simulations to enhance family/caregiver education, an online parental resource center and access to peer support (spanning from hospital to community) and a telehealth post discharge program.
Study: NCT06038136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decreased Neuro Checks overnight
Description: If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
Study: NCT05255952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation of the cardiac plexus
Study: NCT04124029

Intervention type: DEVICE
Intervention: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
Description: No intervention will be used.

Intervention type: DEVICE
Intervention: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
Description: No intervention will be used.

Intervention type: DEVICE
Intervention: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
Description: No intervention will be used.

Intervention type: DEVICE
Intervention: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
Description: No intervention will be used.

Intervention type: DEVICE
Intervention: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
Description: No intervention will be used.

Intervention type: DEVICE
Intervention: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
Description: No intervention will be used.
Study: NCT05753306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given via HIPEC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Undergo robotic gastrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PE/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT06406881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release therapy
Description: Experimental group given MFR along with neck isometric and ocular muscle exercise.~myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patients will be treated 3 seconds to 2 minutes, three days in a week.~Ocular muscle exercise will perform 3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. This exercise will performed 3 sets of 5 repetition 5 days a week.~Total of three sessions .
Study: NCT06389942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Single dose intravenously on day 1
Study: NCT04770935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form:solution for injection Route of administration: intravenous injection
Study: NCT05795946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole food-based B and D vitamins
Description: Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole food-based B and D vitamins
Description: Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
Study: NCT05737095

Intervention type: PROCEDURE
Intervention: Pulmonary ultrasound
Description: Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
Study: NCT06044545

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors
Description: With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used.